Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002, a first-in-class antibody therapy for acromegaly, the company said on Monday. Marea, which is developing medicines for cardioendocrine diseases, is advancing MAR002 as a potential new option for the rare endocrine disorder.
Marriott (MAR) reported earnings 30 days ago. What's next for the stock?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
| Hotels, Restaurants & Leisure Industry | Consumer Discretionary Sector | Anthony G. Capuano Jr. CEO | XMEX Exchange | US5719032022 ISIN |
| US Country | 414,000 Employees | 20 Aug 2026 Last Dividend | 22 Nov 2011 Last Split | 16 Jul 1993 IPO Date |
Marriott International, Inc. is a global leader in the hospitality industry, with a comprehensive portfolio spanning various segments of lodging and residential properties. Founded in 1927 with a single hotel, the company has grown into a worldwide phenomenon, rooted in Bethesda, Maryland. Marriott's business model encompasses the operation, franchising, and licensing of its vast array of properties. Its brand footprint is expansive, covering luxury, premium, and select service segments, and providing a myriad of choices for travelers and residents alike. Over the decades, Marriott has solidified its place at the forefront of the hospitality industry, renowned for its commitment to excellence, innovation, and customer satisfaction.